Riskpilot← Back to searchSign inGet full accessNorming & Son Medical AB
ABActiveOrg 5591577613Nämndemansbacken 108General medical practice activities · NACE 8621Est. 20181 employees
Revenue 2024
SEK 0
EBITDA margin
—
-130% vs 2023
Equity ratio
98.8%
Financial strength
Net profit 2024
SEK -24K
-124% vs 2023
| Revenue | SEK 0 | — |
| EBITDA | SEK -34K | -130% |
| Net profit | SEK -24K | -124% |
| Total assets | SEK 556K | -32% |
| Equity | SEK 550K | -29% |
| Employees | 1 | — |
Legal name
Norming & Son Medical AB
Org number
5591577613
Legal form
Aktiebolag
NACE code
8621 · General medical practice activities
Founded
2 maj 2018
Share capital
SEK 50 000
Employees
1 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas var för sig av ledamoten suppleanten
Company purpose
Aktiebolaget ska bedriva medicinsk verksamhet, försäkrings- medicinsk rådgivning, forskning och utveckling inom medicinsk verksamhet samt konsultverksamhet inom företagsorganisation. Bolaget ska också äga och förvalta fast och lös egendom samt därtill hörande verksamhet.
Address
Nämndemansbacken 108
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 1 021 | 330 | 162 | 154 | 0 |
| Staff expenses | — | — | −1 | −0 | −0 |
| EBITDA | 380 | 187 | 115 | 113 | −34 |
| Depreciation & amort. | −0 | −0 | — | — | — |
| EBIT | 380 | 187 | 115 | 113 | −34 |
| Net financials | −1 | — | 0 | 13 | 10 |
| Profit before tax | 379 | 188 | 115 | 126 | −24 |
| Tax | −81 | −39 | −25 | −26 | — |
| Net profit | 298 | 149 | 91 | 100 | −24 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 1 273 | 1 058 | 915 | 816 | 556 |
| Equity | 1 005 | 974 | 875 | 779 | 550 |
| Long-term debt | 0 | 0 | — | — | — |
| Short-term debt | 268 | 84 | 40 | 38 | 7 |
| Total debt | 268 | 84 | 40 | 38 | 7 |
EBITDA margin
-3373700.0%
This company
15.8%
Market median
-21352632% vs market
20202024
Equity ratio
98.8%
This company
38.2%
Market median
+159% vs market
20202024
Return on equity
-4.3%
This company
18.4%
Market median
-123% vs market
20202024
Net profit margin
-2390000.0%
This company
8.1%
Market median
-29506273% vs market
20202024
Asset turnover
0.00×
This company
1.12×
Market median
-100% vs market
20202024
Debt / equity
0.01×
This company
0.62×
Market median
+98% vs market
20202024
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Bolagsverket / SCB · Period 2020-01-01 – 2020-12-31
No data on file.
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
| Deputy Board Member | 2022 | |
| Board of Directors | 2022 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Norming & Son Medical AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Gunilla Maria Pettersson Norming | Deputy Board Member | 0 companies |
| Ulf Norming | Board of Directors | 0 companies |